LCZ696 (sacubitril/valsartan)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Conditions
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Trial Timeline
Mar 8, 2016 → Nov 29, 2017
NCT ID
NCT02690974About LCZ696 (sacubitril/valsartan)
LCZ696 (sacubitril/valsartan) is a approved stage product being developed by Novartis for Hearth Failure With Reduced Ejection Fraction (HFrEF). The current trial status is completed. This product is registered under clinical trial identifier NCT02690974. Target conditions include Hearth Failure With Reduced Ejection Fraction (HFrEF).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02887183 | Approved | Completed |
| NCT02690974 | Approved | Completed |